<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377271</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000848-14</org_study_id>
    <nct_id>NCT02377271</nct_id>
  </id_info>
  <brief_title>ENDOTHELION Study Group: Effect of Bosentan in NAION Patients</brief_title>
  <acronym>ENDOTHELION</acronym>
  <official_title>Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after
      glaucoma in the population aged over 50 years. The visual prognosis of the condition is
      unfavorable in the great majority of cases, with significant effects on the visual field and
      vision. The severity of the unilateral condition is also associated with bilateralization in
      15% at 5 years. There is no effective treatment for the acute phase of the disease or to
      reduce the rate of bilateralization. In this context, it is essential to develop new
      therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve
      damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of our study will be to compare the treatment with bosentan to placebo for
      8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional (visual
      acuity, visual field). The primary endpoint will be the improvement of the visual field, a
      major criterion of the affected visual function in this disease.

      The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the
      effectiveness of drug treatment in the absence of continuous positive airway pressure (set up
      after three months if necessary, feasible confounding factor for the evaluation of results ),
      the period of three months is sufficient to assess the anatomical and functional recovery
      (disappearance of papilledema).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>automated visual field (Humphrey 30-2 SITA-standard)</measure>
    <time_frame>3 month</time_frame>
    <description>Humphrey 30-2 SITA-standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity (ETDRS scale)</measure>
    <time_frame>6, 12 and 24 month</time_frame>
    <description>ETDRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optic nerve fiber layer thickness</measure>
    <time_frame>3, 6, 12 and 24 month</time_frame>
    <description>OCT measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field for healthy eye and NAION eye</measure>
    <time_frame>3, 6, 12 and 24 month</time_frame>
    <description>Humphrey 30-2 and 60-4 sita-standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker and prepro-endothelin dosing</measure>
    <time_frame>3 month</time_frame>
    <description>RANTES, MCP-1, TNF-α, INF-γ, IL-6, IL-10 and TGF-β</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field for controlateral eye</measure>
    <time_frame>24 month</time_frame>
    <description>Humphrey 30-2 sita-standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 and 12 month</time_frame>
    <description>VFQ-25</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drug , twice a day, during eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>treatment by bosentan or placebo is randomized , 125 mg twice a day</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>treatment by bosentan or placebo is randomized</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non arteritic ischemic optic neuropathy (NAION) with onset &lt; 21 days with or without
             sleep apnea

          -  Negative pregnancy test and use of a effective conraceptive methode for non-menauposal
             wemen

          -  Signed informed consent

          -  Person affiliated to social security

          -  Patient with systolic pressure ≥ 100 mmHg

        Exclusion Criteria:

          -  Pregnant, parturient or nursing woman

          -  Woman of child bearing potential without an effective contracptive method (use of
             hormonal contraception only is not considered effective)

          -  Other intercurrent ocular pathology, acute or chronic

          -  Simultaneaous bilateral NAION, ≤ 1 month

          -  Signs of another inflammatory neuropathy (Horton disease, optical nevritis,
             inflammatory optical neuropathy history)

          -  Signs of a retinal pathology

          -  Signs of a neuroretinis

          -  Patient with systolic pressure &lt; 100 mmHg

          -  Patient with orthostatic hypotension

          -  Neurologic history : vascular or tumoral

          -  Systemic inflammatory pathology

          -  Known allergy to Bosentan

          -  Moderate to severe hepatic failure

          -  Glomerular filtration rate &lt; 30 ml/min/1,73 m2

          -  Patient treated with drugs which efficacy can be lowered by CYP450, CYP2C9, CYP3A4 and
             CYP 2C19 activation

          -  Patient treated with amiodarone

          -  Patient treated with forbidden drugs for the study

          -  Patient treated with systemic corticotherapy

          -  Subject under juridic protection or not able to give informed consent, subject
             deprived of liberty

          -  Subject participaing to another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Pr CHIQUET, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Pr CHIQUET, Prof, MD, PhD</last_name>
    <email>CChiquet@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baidi Zineb, PhD</last_name>
    <phone>+33 476766660</phone>
    <email>ZBaidi@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan MILEA, MD</last_name>
      <phone>0241353274</phone>
      <email>dmilea@free.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie LERUEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric GAGNADOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascaline PRIOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Bénédicte ROUGIER, MD</last_name>
      <phone>05 57 82 12 16</phone>
      <email>marie-benedicte.rougier@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François KOROBELNIK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre PHILIP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EMILIE TOURNAIRE MARQUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Arthur MICOULAUD FRENCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe CHIQUET, MD</last_name>
      <phone>04 76 76 55 16</phone>
      <email>CChiquet@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Florent APTEL, MD</last_name>
      <phone>04 76 76 55 48</phone>
      <email>faptel@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Paul ROMANET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis PEPIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud TAMISIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAUNOIS-ROLLINAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand TOUSSAINT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier ORMEZZANO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole BURILLON, MD</last_name>
      <phone>0472116217</phone>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lucie ABOUAF, MD</last_name>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric GORMAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain BECCAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophtalmological fondation of Rothschild + Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine VIGNAL, MD</last_name>
      <phone>0148036222</phone>
      <email>cvignal@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric LAMIREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Pia ORTHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GAIN, MD</last_name>
      <phone>0477127793</phone>
      <email>philippe.gain@univ-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire GUILLEMOT, MD</last_name>
      <phone>0673169519</phone>
      <email>claire.guillemot@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles THURET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle COURT-FORTUNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

